Elucid Moves Headquarters to Boston’s Back Bay, Preparing for Commercial Growth

Share This Post

Key Highlights

  • Elucid relocates to 399 Boylston Street, Boston.
  • Move supports commercialization of flagship plaque analysis software.
  • New office fosters collaboration and employee wellness.
  • Follows $80M Series C fundraise led by Elevage Medical Technologies.

Source: Business Wire

Notable Quote

  • “This new environment will foster stronger team connections and enhance our collaborative efforts, bringing our hybrid workforce together more effectively to develop and deliver meaningful products that improve patient care.”  Amy Kruglak, Vice President of People at Elucid

SoHC's Take

Elucid’s strategic move to Boston’s Back Bay positions the company advantageously for its next phase of growth. The modern, well-equipped headquarters will not only support the development and commercialization of its groundbreaking PlaqueIQ software but also provide an environment conducive to collaboration and employee well-being. With the backing of an $80 million Series C fundraise, Elucid is well-poised to advance its mission of improving patient care through innovative cardiovascular imaging solutions. This relocation is a significant step in Elucid’s three-year strategic plan, reinforcing its commitment to tackling the global challenge of cardiovascular disease with cutting-edge technology.

More To Explore

Total
0
Share